Want to see PRTCY full AI Analyst Report?
PureTech Health (PRTCY) Stock Price & Analysis
PRTCY Stock Chart & Stats
- Day’s Range
- $16.02 - $16.02
- 52-Week Range
- $14.23 - $19.92
- Previous Close
- $15.73
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $385.74M
- Enterprise Value
- $243.44M
- Total Cash (Recent Filing)
- $278.89M
- Total Debt (Recent Filing)
- $19.76M
- Price to Earnings (P/E)
- 160.0
- Beta
- 0.33
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway And Lower Burn
A runway extending through 2028 gives PureTech time to advance programs without relying immediately on capital markets. The planned reduction in annual cash burn also improves capital efficiency, preserves strategic flexibility, and supports continued investment through multiple development milestones.
Capital-efficient Hub-and-spoke Model
The hub-and-spoke structure can reduce the funding burden at the parent company while preserving participation in successful affiliated programs. Retained equity, royalties, and milestones create multiple routes to value realization and support a repeatable portfolio-building strategy.
Clinical And Regulatory Pipeline Progress
Regulatory clarity and Fast Track status can improve the development path for LYT-200 and help focus the next trial on an agreed design. Positive Phase Ib results and Phase II readiness provide tangible advancement beyond discovery, strengthening the portfolio’s longer-term value potential.
Bears Say
Persistent Negative Cash Generation
Sustained negative operating and free cash flow means PureTech is not yet funding its activities through recurring internal cash generation. Continued burn can reduce financial resources over time and make execution increasingly dependent on monetizations, partnerships, or additional financing.
Small, Volatile Revenue And Recurring Losses
Limited and inconsistent revenue visibility makes results dependent on development progress, licensing, and portfolio monetization rather than a stable commercial base. Recurring operating losses reduce earnings durability and leave less internally generated funding for advancing the pipeline.
External Funding Requirements For Development
Pending financing for major clinical programs introduces execution and timing risk because trial progress depends partly on securing outside capital. Additional funding needs may also constrain program choices or require less favorable structures if financing conditions or partner interest weaken.
PRTCY FAQ
What was PureTech Health’s price range in the past 12 months?
What is PureTech Health’s market cap?
When is PureTech Health’s upcoming earnings report date?
How were PureTech Health’s earnings last quarter?
Is PureTech Health overvalued?
Does PureTech Health pay dividends?
What is PureTech Health’s EPS estimate?
How many shares outstanding does PureTech Health have?
What happened to PureTech Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PureTech Health?
What is the TipRanks Smart Score and how is it calculated?
PureTech Health Stock Smart Score
Company Description
PureTech Health
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert William Henry Lyne
- Employees
- 90
- Website
- www.puretechhealth.com
- Address
- 6 Tide Street, Boston, MA, 02210, US
PureTech Health (PRTCY) Earnings & Revenues
PRTCY Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, highlighting successful financing and IPO execution, clinical and regulatory progress, a strong cash runway, lower expected go-forward cash burn and an innovation pipeline ahead of its stated target. The main negatives were the material downgrade in estimated future Cobenfy proceeds, the first-half cash balance decline, higher first-half operating expenses and pending financing requirements for Gallop and Celea.
View all PRTCY earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 8 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 9 | 0 | 3 |
